AI Article Synopsis

  • The study aimed to distinguish between placenta accreta spectrum (PAS) and uterine-scar dehiscence using standardized ultrasound techniques, which is often difficult even for experts.
  • A retrospective cohort study was conducted with women who had previous Cesarean deliveries and current pregnancies with low-lying placenta conditions, analyzing various ultrasound markers to classify cases of PAS and non-PAS.
  • Out of 150 cases reviewed, 144 were included in the analysis, resulting in 89 PAS cases, 23 uterine-scar dehiscence cases, and 32 cases with uncomplicated low-lying placenta or placenta previa.

Article Abstract

Objective: Accurate differentiation between placenta accreta spectrum (PAS) and uterine-scar dehiscence with underlying non-adherent placenta is often challenging, even for PAS experts, both prenatally and intraoperatively. We investigated the use of standardized two-dimensional grayscale ultrasound and Doppler imaging markers in differentiating between these closely related, yet distinct, conditions.

Methods: This was a retrospective cohort study conducted in two centers with specialized PAS services. All consecutive women with at least one previous Cesarean delivery and a current pregnancy with a low-lying placenta or placenta previa, for whom detailed prenatal ultrasound, management and outcome information was available for review by the research team, were included. PAS was diagnosed clinically by the abnormal adherence of the placenta to the uterus. The PAS cases were classified using the International Federation of Gynecology and Obstetrics clinical classification. Grade 1 was considered low-grade PAS while Grades 2 and 3 were classified as high-grade PAS. The ultrasound markers were categorized according to their underlying pathophysiology, including lower uterine segment (LUS) remodeling, uteroplacental vascular remodeling and serosal hypervascularity. The combined ultrasound features were analyzed among the PAS and non-PAS subgroups using the chi-square test or Fisher's exact test, and univariable and multivariable logistic regression analysis. Additionally, receiver-operating-characteristics (ROC) curves were used to evaluate the diagnostic accuracy of the combined ultrasound features in differentiating between high-grade PAS and uterine-scar dehiscence.

Results: Out of the 150 cases retrieved, six cases were excluded for not meeting the eligibility criteria. The included 144 cases comprised 89 cases of PAS, 23 cases of uterine-scar dehiscence and 32 cases of uncomplicated low-lying placenta or placenta previa. Among the PAS cases, there were 16 cases of low-grade PAS and 73 of high-grade PAS. Combined signs of LUS remodeling were present in most cases of uterine-scar dehiscence (20/23 (87.0%)) and high-grade PAS (67/73 (91.8%)) (P = 0.444), while these signs were absent in cases of low-grade PAS (0/16) and uncomplicated low-lying placenta or placenta previa (0/32). A subgroup analysis of cases with all LUS remodeling features present revealed that the combined signs of serosal hypervascularity (adjusted odds ratio (aOR), 41.2 (95% CI, 7.5-225.3)) and uteroplacental vascular remodeling (aOR, 116.0 (95% CI, 15.3-878.3)) were significantly associated with high-grade PAS. Diagnostic accuracy testing within this subgroup revealed an area under the ROC curve (AUC) of 0.90 (95% CI, 0.81-0.99), sensitivity of 89.6% (95% CI, 79.7-95.7%) and specificity of 90.0% (95% CI, 68.3-98.8%) for the diagnosis of high-grade PAS when all signs of uteroplacental vascular remodeling were present. If both signs of serosal hypervascularity were present, the AUC was 0.84 (95% CI, 0.74-0.95) with a sensitivity of 83.6% (95% CI, 72.5-91.5%) and specificity of 85.0% (95% CI, 62.1-96.8%) for the diagnosis of high-grade PAS.

Conclusions: The combined ultrasound markers of LUS remodeling are common in both high-grade PAS and uterine-scar dehiscence, while the combined features of abnormal vascularity (uteroplacental vascular remodeling and serosal hypervascularity) are specific to high-grade PAS. Understanding these pathophysiological differences would enhance the diagnostic accuracy of ultrasound in distinguishing between these two conditions. © 2024 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

Download full-text PDF

Source
http://dx.doi.org/10.1002/uog.29144DOI Listing

Publication Analysis

Top Keywords

high-grade pas
32
uterine-scar dehiscence
20
pas
19
lus remodeling
16
uteroplacental vascular
16
vascular remodeling
16
serosal hypervascularity
16
ultrasound markers
12
pas uterine-scar
12
low-lying placenta
12

Similar Publications

Article Synopsis
  • The study aimed to distinguish between placenta accreta spectrum (PAS) and uterine-scar dehiscence using standardized ultrasound techniques, which is often difficult even for experts.
  • A retrospective cohort study was conducted with women who had previous Cesarean deliveries and current pregnancies with low-lying placenta conditions, analyzing various ultrasound markers to classify cases of PAS and non-PAS.
  • Out of 150 cases reviewed, 144 were included in the analysis, resulting in 89 PAS cases, 23 uterine-scar dehiscence cases, and 32 cases with uncomplicated low-lying placenta or placenta previa.
View Article and Find Full Text PDF

Objective: We report the first documented case of concurrent ectopic complete hydatidiform mole (CHM) and high-grade serous carcinoma (HGSC) of the fallopian tube, associated with unique histologic features and mutations in the HGSC.

Case Report: The patient presented with pelvic pain and vaginal bleeding. Laboratory examination revealed a positive urine pregnancy test and high serum beta-human chorionic gonadotropin (β-hCG).

View Article and Find Full Text PDF

[Not Available].

Bull Cancer

October 2024

Service d'oncologie endocrinienne, Département d'imagerie, Gustave-Roussy, F-94805 Villejuif, France.

MANAGING MEDULLARY THYROID CARCINOMA IN 2024: Medullary thyroid carcinoma is a rare neuroendocrine thyroid cancer with a heterogeneous prognosis which has the particularity of being associated with a RET gene mutation, germline in 20-25% of cases in the context of multiple endocrine neoplasia type 2 (NEM2), and somatic in 70% of sporadic cases. It is often diagnosed on a thyroid nodule or in the context of genetic screening. Calcitonin is a biological marker, used for diagnosis, monitoring of therapeutic response and prognostic evaluation.

View Article and Find Full Text PDF
Article Synopsis
  • Undifferentiated embryonal sarcoma of the liver is a rare cancer mostly affecting children, and is even less common in adults; proper imaging is crucial to avoid misdiagnosing it with more common liver masses.
  • A 37-year-old Chinese woman presented with abdominal pain and underwent multiple imaging tests revealing a cystic-solid liver nodule, initially thought to be benign.
  • The definitive indication of malignancy came from a PET-CT scan, which showed abnormal F-fluorodeoxyglucose uptake, prompting the correct diagnosis of undifferentiated embryonal sarcoma of the liver.
View Article and Find Full Text PDF
Article Synopsis
  • Neuroepithelial tumors resembling pilocytic astrocytoma have been reclassified by the WHO as high-grade astrocytoma with piloid features (HGAP), highlighting their unique characteristics and rarity.
  • An 83-year-old woman experienced progressive lower-extremity weakness, leading to the discovery of a neuroepithelial tumor in the conus medullaris, which is an uncommon site for this type of tumor.
  • The case emphasizes the need for clinicians to consider HGAP in differential diagnoses for spinal cord masses, as it represents a novel classification of a rare condition.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!